| Today's Big NewsJan 10, 2023 |
|
Thursday, January 19, 2023 | 11:00am ET In this webinar, hear how Novartis uses social data from public forums worldwide to understand the educational and emotional needs of patients with Myelodysplastic Syndromes (MDS), and thereby create more targeted solutions to meet these needs. Register now.
|
|
| By Eric Sagonowsky Pfizer was among the drugmakers most elevated by the COVID-19 pandemic, and, going forward, the pharma giant has no plans to give up on its current momentum. |
|
|
|
By Paige Minemyer SAN FRANCISCO—The top brass at CVS Health reiterated Tuesday that the healthcare giant is still plotting its move into primary care but emphasized that they want to ensure the next steps are the right ones. |
By Annalee Armstrong Karuna Therapeutics is 24 months out from a hotly anticipated schizophrenia drug launch and the industry is buzzing with rumors that the biotech will seek a Big Pharma partnership or other deal for commercialization. |
By Andrea Park In interviews with Fierce Medtech during the annual J.P. Morgan Healthcare Conference on Monday, leaders from Freenome, Babson Diagnostics and Immunexpress discussed their ongoing plans to make a wide range of blood tests as broadly accessible and as simple to use as possible. |
|
Tuesday, January 24, 2023 | 11am ET / 8am PT Your CRO is a finalist in a project bid and clinical supplies are one of the aspects that you will manage on behalf of the client via a partner. Register now.
|
|
By Zoey Becker Biogen's new CEO, Chris Vienbacher, has a lot of mess to clean up. Instead of pushing towards big M&A, which many expected of him due to his background at the helm of Sanofi, he has in-house work to do first as he aims to do some "redefinition" of the company. |
By Annie Burky Teladoc CEO Jason Gorevic used the telehealth company's Monday presentation at the J.P. Morgan Healthcare Conference to emphasize a steady march to telehealth permanence within healthcare. |
By Conor Hale Investments in international manufacturing facilities and component contracts are setting ResMed up to better meet patient needs in 2023 and beyond. |
By Annalee Armstrong Sage Therapeutics is trying to pick up pieces of the depression market that have long been left behind, including patients who are not fully served by existing meds and postpartum mothers who have never had an easy, fast option to try. |
By Ben Adams AbbVie’s Rinvoq took December’s TV drug ad spend crown, and its fierce rival in Sanofi and Regeneron’s Dupixent was in second place as both replicated their November positions but spent less than the month before. |
By Heather Landi Startup Carbon Health is partnering with CVS Health to pilot its primary and urgent care services in the drugstore giant's retail stores. CVS' corporate venture arm also led a $100 million investment to accelerate Carbon Health's expansion into new markets. |
By Andrea Park In an interview with Fierce Medtech at the J.P. Morgan Healthcare Conference, Invitae CEO Kenneth Knight discussed how the nearly two decades he spent at General Motors, Caterpillar and Amazon prepared him to lead a genetic testing company. |
By Eric Sagonowsky,Zoey Becker,Angus Liu,Fraiser Kansteiner,Kevin Dunleavy On the second day of the J.P. Morgan Healthcare Conference, GSK, Bayer, Roche and many others are set to share updates about their operations. |
By Gabrielle Masson,Max Bayer,Annalee Armstrong,James Waldron All you need to know from the second day of the J.P. Morgan Healthcare Conference. |
By Heather Landi,Paige Minemyer All the latest healthcare and health tech news from the J.P. Morgan Healthcare Conference in San Francisco. |
Fierce podcastsDon't miss an episode |
| | This week on “The Top Line,” we discuss the biotech industry’s rotten tomatoes. Plus, we cover the drug approvals of last year, a congressional report on Biogen's "inappropriate" communications with the FDA and other top headlines from this week. |
|
|---|
|
|
|
Tuesday, January 24, 2023 | 11am ET / 8am PT UGTs are the most common enzymes involved in metabolism after CYP enzymes, followed by numerous hydrolases, carbonyl reductases, aldehyde oxidase and other enzymes. Hear Dr. Brian Ogilvie discuss case studies and strategies to address non-CYP related metabolism questions in your drug’s safety assessment. Register now.
|
|
| WhitepaperThis paper explores how Medical Affairs is adapting medical communications to meet the demands of a new environment (part 5 in a series). Sponsored by: Blue Matter, strategic consultants in the life sciences |
| On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
| Executive Summary Readers will learn manufacturing by Design Builds on Quality by Design, De-risking the Tech Transfer Process, and more. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| WhitepaperLearn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| |
|
